Stock Scorecard



Stock Summary for Instil Bio Inc (TIL) - $24.87 as of 11/19/2024 2:20:08 PM EST

Total Score

7 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for TIL

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for TIL

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for TIL

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for TIL

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for TIL (32 out of 90)

Stock Price Rating (Max of 10) 7
Historical Stock Price Rating (Max of 10) 1
Stock Price Trend (Max of 10) 0
Book Value (Max of 10) 8
Book Value to Price (Max of 10) 8
Analyst Buy Ratings (Max of 5) 2
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 3
Price to Earnings (Max of 10) 0

Latest News for for TIL

Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy 11/15/2024 7:38:00 PM
BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock Up 11/14/2024 3:45:00 PM
Summit Therapeutics Stock: Sell or Hold Before Q3 Earnings? 10/24/2024 1:28:00 PM
Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising? 10/24/2024 9:13:00 AM
Summit Stock Skyrockets Nearly 700% YTD: Time to Sell or Hold? 10/23/2024 1:41:00 PM
2 Stocks Up Over 700% in 2024 That Could Soar Even Further 9/25/2024 8:56:00 AM
Steelcase Reports Weak Sales, Joins American Healthcare REIT And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Steelcase ( NYSE:SCS ) 9/19/2024 12:24:00 PM
Here's Why Everyone's Talking About Summit Therapeutics 9/17/2024 8:24:00 AM
Crude Oil Surges Over 1%; Instil Bio Shares Plunge - NuCana ( NASDAQ:NCNA ) 9/16/2024 4:31:00 PM
Instil Bio Stock Skyrockets 641% in One Week: Here's Why 9/16/2024 3:23:00 PM

Financial Details for TIL

Company Overview

Ticker TIL
Company Name Instil Bio Inc
Country USA
Description Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer patients. The company is headquartered in Dallas, Texas.
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter 9/30/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 24.87
Price 4 Years Ago 0.00
Last Day Price Updated 11/19/2024 2:20:08 PM EST
Last Day Volume 67,543
Average Daily Volume 159,976
52-Week High 92.00
52-Week Low 6.07
Last Price to 52 Week Low 309.72%

Valuation Measures

Trailing PE N/A
Industry PE 120.49
Sector PE 40.32
5-Year Average PE -55.23
Free Cash Flow Ratio 24.38
Industry Free Cash Flow Ratio 15.59
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 12.90
Total Cash Per Share 1.02
Book Value Per Share Most Recent Quarter 34.72
Price to Book Ratio 0.88
Industry Price to Book Ratio 5.50
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 55,329.79
Industry Price to Sales Ratio Twelve Trailing Months 20.11
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 1
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 6,503,900
Market Capitalization 161,751,993
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 30.06%
Reported EPS 12 Trailing Months -18.39
Reported EPS Past Year -8.58
Reported EPS Prior Year -3.09
Net Income Twelve Trailing Months -75,165,000
Net Income Past Year -156,087,000
Net Income Prior Year -223,177,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00

Balance Sheet

Total Cash Most Recent Quarter 6,663,000
Total Cash Past Year 150,356,000
Total Cash Prior Year 260,920,000
Net Cash Position Most Recent Quarter -75,510,000
Net Cash Position Past Year 68,929,000
Long Term Debt Past Year 81,427,000
Long Term Debt Prior Year 72,350,000
Total Debt Most Recent Quarter 82,173,000
Equity to Debt Ratio Past Year 0.73
Equity to Debt Ratio Most Recent Quarter 0.68
Total Stockholder Equity Past Year 225,829,000
Total Stockholder Equity Prior Year 363,605,000
Total Stockholder Equity Most Recent Quarter 176,332,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -58,576,000
Free Cash Flow Per Share Twelve Trailing Months -9.01
Free Cash Flow Past Year -102,692,000
Free Cash Flow Prior Year -264,753,000

Options

Put/Call Ratio 0.00
Has Options False
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -2.74
MACD Signal -2.97
20-Day Bollinger Lower Band -12.29
20-Day Bollinger Middle Band 29.94
20-Day Bollinger Upper Band 72.17
Beta 1.74
RSI 40.43
50-Day SMA 54.39
150-Day SMA 97.49
200-Day SMA 0.00

System

Modified 11/19/2024 2:20:10 PM EST